Get the Stockscreener App
3.67
13.98%
0.45
After Hours:
3.61
-0.06
-1.63%
Kala Bio Inc stock is traded at $3.67, with a volume of 108.08K.
It is up +13.98% in the last 24 hours and up +5.76% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$3.22
Open:
$3.27
24h Volume:
108.08K
Relative Volume:
1.64
Market Cap:
$23.67M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.2943
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+7.31%
1M Performance:
+5.76%
6M Performance:
-45.22%
1Y Performance:
-45.47%
1-Day Range:
$3.27
$3.8529
1-Week Range:
$3.159
$3.8529
52-Week Range:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
3.67 | 22.07M | 5.75M | -38.96M | -32.63M | -12.47 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA BIO: Q1 Earnings Snapshot - New Haven Register
KALA Focuses on Advancing KPI-012 Development Amid Pivotal Trials | KALA Stock News - GuruFocus
Kala Pharmaceuticals reports Q1 EPS ($1.41) vs ($4.20) last year - TipRanks
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
KALA's PCED Drug Could Reach 100,000 PatientsQ3 Trial Results Coming - Stock Titan
Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World
Equities Analysts Issue Forecasts for Cryoport Q2 Earnings - Defense World
B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World
Q2 EPS Estimate for Cogent Biosciences Lifted by Analyst - Defense World
Q2 EPS Estimates for Core Scientific Lifted by HC Wainwright - Defense World
KALA BIO (KALA) Projected to Post Quarterly Earnings on Tuesday - Defense World
Q2 Earnings Forecast for Cryoport Issued By Leerink Partnrs - Defense World
KALA BIO (KALA) Projected to Post Earnings on Tuesday - Defense World
Fluence Energy, Inc. (NASDAQ:FLNC) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Dimensional Fund Advisors LP Sells 5,772 Shares of Turning Point Brands, Inc. (NYSE:TPB) - Defense World
Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World
Geode Capital Management LLC Has $426,000 Stake in Sidus Space, Inc. (NASDAQ:SIDU) - Defense World
Geode Capital Management LLC Increases Position in Forte Biosciences, Inc. (NASDAQ:FBRX) - Defense World
Geode Capital Management LLC Boosts Holdings in KALA BIO, Inc. (NASDAQ:KALA) - Defense World
Geode Capital Management LLC Has $403,000 Stake in Mobix Labs, Inc. (NASDAQ:MOBX) - Defense World
Wix.com Ltd [WIX] Insider Activity: An Update for Investors - knoxdaily.com
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
Recent Insider Activity Could Benefit Insperity Inc (NSP) - knoxdaily.com
Analyzing Kala Bio Inc (KALA) After Recent Trading Activity - knoxdaily.com
International Business Machines Corp [IBM] Stock sold by Insider Thomas Robert David for $6.72 million - knoxdaily.com
Aurora Cannabis Inc [ACB] Investment Guide: What You Need to Know - knoxdaily.com
Insider Sale Alert: Angi Inc [ANGI] – Is it Time to sell? - knoxdaily.com
Kala Bio Inc (KALA) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Kala Bio Inc (KALA) Stock: A Year of Market Fluctuations - investchronicle.com
Piper Sandler gives a Neutral recommendation for RxSight Inc (RXST) - knoxdaily.com
Oppenheimer maintains Kala Bio stock Outperform with $15 target By Investing.com - Investing.com Canada
Kala Bio announces executive retention bonuses - Investing.com Australia
KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com - Investing.com South Africa
Kala Bio announces executive retention bonuses By Investing.com - Investing.com South Africa
Kala Pharmaceuticals Announces Executive Retention Agreements - TipRanks
KALA stock touches 52-week low at $3.4 amid market challenges - Investing.com
Dynatrace, Inc. (NYSE:DT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Darling Ingredients Inc. (NYSE:DAR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Truist Financial Lowers Bank of New York Mellon (NYSE:BK) Price Target to $90.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for KALA BIO (NASDAQ:KALA) - Defense World
Kala Pharmaceuticals stock hits 52-week low at $4.05 - Investing.com India
Kala Pharmaceuticals stock hits 52-week low at $4.05 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Kala Bio, target at $15 By Investing.com - Investing.com Canada
Kala Bio Inc Reports Q4 2024 Earnings: EPS Misses Estimate at -2 - GuruFocus
Simply Good Foods (SMPL) Expected to Announce Earnings on Wednesday - The AM Reporter
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock - Investing.com Australia
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock By Investing.com - Investing.com UK
KALA BIO: Q4 Earnings Snapshot - Huron Daily Tribune
KALA BIO Advances Eye Disease Therapies with New Funding - TipRanks
KALA BIO Inc. (KALA) reports earnings - Quartz
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brazzell Romulus K | SEE REMARKS |
Jan 06 '25 |
Sale |
7.63 |
2,446 |
18,663 |
92,418 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jan 06 '25 |
Sale |
7.63 |
5,779 |
44,094 |
280,076 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jan 06 '25 |
Sale |
7.63 |
1,706 |
13,017 |
68,581 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):